Your browser is no longer supported. Please, upgrade your browser.
MRK Merck & Co. Inc. daily Stock Chart
Merck & Co. Inc.
IndexDJIA S&P500 P/E15.49 EPS (ttm)3.42 Insider Own0.04% Shs Outstand2.82B Perf Week-2.65%
Market Cap149.23B Forward P/E13.87 EPS next Y3.82 Insider Trans-25.69% Shs Float2.82B Perf Month-9.74%
Income9.85B PEG2.24 EPS next Q0.92 Inst Own75.30% Short Float1.07% Perf Quarter-10.24%
Sales40.25B P/S3.71 EPS this Y176.90% Inst Trans-0.34% Short Ratio2.99 Perf Half Y-7.18%
Book/sh16.44 P/B3.22 EPS next Y8.77% ROA9.60% Target Price65.29 Perf Year-9.69%
Cash/sh4.04 P/C13.12 EPS next 5Y6.92% ROE21.00% 52W Range45.69 - 62.63 Perf YTD-5.24%
Dividend1.80 P/FCF90.66 EPS past 5Y-6.30% ROI0.50% 52W High-15.41% Beta0.51
Dividend %3.40% Quick Ratio1.30 Sales past 5Y9.00% Gross Margin63.00% 52W Low15.96% ATR1.84
Employees70000 Current Ratio1.60 Sales Q/Q-10.50% Oper. Margin39.60% RSI (14)36.95 Volatility2.33% 3.07%
OptionableYes Debt/Eq0.57 EPS Q/Q-64.70% Profit Margin24.50% Rel Volume1.30 Prev Close52.53
ShortableYes LT Debt/Eq0.52 EarningsJul 28 BMO Payout51.40% Avg Volume10.09M Price52.98
Recom2.40 SMA20-6.74% SMA50-7.99% SMA200-8.95% Volume13,113,434 Change0.86%
Jun-17-15Initiated Piper Jaffray Neutral
Apr-29-15Reiterated UBS Buy $64 → $68
Apr-29-15Reiterated Argus Buy $66 → $70
Apr-30-14Reiterated Argus Buy $62 → $66
Apr-11-14Reiterated MKM Partners Buy $64 → $70
Feb-05-14Reiterated Argus Buy $54 → $62
Jan-14-14Reiterated MKM Partners Buy $59 → $64
Jun-03-13Reiterated MKM Partners Buy $54 → $59
Apr-15-13Reiterated Barclays Overweight $45 → $60
Feb-04-13Reiterated MKM Partners Buy $51 → $52
Feb-04-13Reiterated Barclays Overweight $46 → $45
Nov-20-12Upgrade MKM Partners Neutral → Buy $47 → $51
Oct-17-12Reiterated MP Advisors Outperform $45 → $50
Jul-30-12Reiterated UBS Buy $45 → $50
Jul-13-12Upgrade MP Advisors Market Perform → Outperform $45
Feb-03-12Reiterated Barclays Capital Overweight $38 → $40
Feb-03-12Downgrade MKM Partners Buy → Neutral $42 → $40
Nov-29-11Initiated MKM Partners Buy $38
Sep-14-11Reiterated Barclays Capital Overweight $41 → $38
May-16-11Reiterated UBS Buy $40 → $42
Sep-02-15 04:21PM  UK Study Indicates That The Cardiovascular Risk Of Celebrex No Different From Other Pain Drugs at Forbes
09:06AM  FDA approves Tesaro's drug for chemotherapy-induced nausea Reuters
08:00AM  FDA Approves Pediatric Indication for EMEND® (aprepitant) Capsules in Combination with Other Antiemetic Agents Business Wire
Sep-01-15 02:42PM  Organovo CEO Keith Murphy: 'People Are Missing The Forest For The Trees'
09:00AM  New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin) Business Wire
Aug-31-15 09:40AM  Merck: A Great Dividend Stock for Retirees at Kiplinger
Aug-29-15 02:43PM  Did This Clinical Study Just Show Merck's Best-Selling Drug the Door? at Motley Fool
12:01AM  Bargains Beckon as U.S. Stocks Bottom at
Aug-28-15 04:04PM  FDA: Some Diabetes Drugs Can Cause Joint Pain at The Wall Street Journal
01:37PM  FDA warns of severe joint pain risk with DPP-4 diabetes drugs Reuters
12:58PM  Credit Suisse's 8 Pharmaceutical Stocks With 'Significant' Upside at TheStreet
09:30AM  The Zacks Analyst Blog Highlights: Merck & Co, Apple, Visa, Microsoft and Intel
Aug-27-15 05:00PM  How Did Novavax Perform in 2Q15?
10:17AM  5 Stocks That Led Dow to 3rd Biggest Gain
02:03AM  Ablynx burns more cash in first half of 2015
Aug-26-15 03:04PM  U.S. stocks on track to snap 6-session losing streak at MarketWatch +6.35%
02:48PM  Is the bounce back real?
02:36PM  Apple, Intel, Exxon and others lead Dow out of six day slump
02:00PM  Is the bounce back real?
12:34PM  50 Beaten-Down Stocks For Your Buying Pleasure at
08:05AM  Short Sellers Have Mixed Feelings on Major Pharma at 24/7 Wall St.
Aug-25-15 04:50PM  Merck sues Taiwan company over generic antibiotic product at -5.22%
04:06PM  Dow, S&P close lower in biggest reversal since Oct. 08 at CNBC
02:34PM  Nine Explanations For Why The FDA Is Approving Almost Every New Drug Application at Forbes
Aug-24-15 05:50PM  Biggest moves off the low
Aug-21-15 03:21PM  The science that may help Jimmy Carter at
01:35PM  4 Defensive Stocks Acting as a Buffer Against the Market Sell-Off at 24/7 Wall St.
09:07AM  Jimmy Carter, Melanoma And The Promise Of Immunotherapy In The Elderly at Forbes
Aug-20-15 08:40PM  New Skin Cancer Drugs Delayed (but Investors and Patients Needn't Worry) at Motley Fool
05:03PM  Diabetes drug shows 1st protection from heart complications
04:08PM  Lilly Diabetes Drug Jardiance Improves Heart Health at Investor's Business Daily
03:17PM  Stocks Smacked Lower Again; Growth Stocks Hit; Disney Craters at Investor's Business Daily
10:40AM  Stocks Open In Crumple Zone; Valeant Slides, Tech Data Spikes at Investor's Business Daily
08:30AM  New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Will Be Presented at the European Society of Cardiology Congress Business Wire
Aug-19-15 04:20PM  Merck's Keytruda under FDA Review for First-Line Melanoma
03:30PM  This startup may have just revolutionized Type 2 diabetes treatment at Fortune
Aug-18-15 11:46PM  Intarcias Diabetes Treatment Clears Key Test at The Wall Street Journal
08:44PM  Intarcias Diabetes Implant Beats Mercks Januvia in Trial at Bloomberg
08:37PM  Boston firms diabetes treatment beats $6B Merck drug in head-to-head trial at
08:00PM  Intarcia's Diabetes Treatment Clears Key Test at The Wall Street Journal
07:05PM  Pfizers Revised Financial Guidance for 2015
05:43PM  Something Big Is Happening With Big Pharma at Motley Fool
01:27PM  Merck recalls chemotherapy drug over child-proof cap cracks
01:17PM  Merck Recalls TEMODAR® and Temozolomide Bottles with Cracked Caps Due to Failure to Meet ChildResistant Closure Requirement Business Wire
12:23PM  Consumer watchdog announces Rite Aid, Ikea and Merck product recalls at MarketWatch
08:22AM  4 Top Pharma Stocks That Should Outperform Out To 2016 at 24/7 Wall St.
08:00AM  FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Mercks Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review Business Wire
Aug-16-15 08:37AM  Did Merck and NewLink Genetics Just Cure Ebola? at Motley Fool
Aug-14-15 05:43PM  Charles Brandes Beefs Up Second-Most Valuable Stake in Portfolio
01:07PM  Kyle Bass' pharma plays
10:06AM  Pfizers Revenue Falls by 7% in 2Q15
08:00AM  Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal PR Newswire
Aug-13-15 04:01PM  The 4 Stocks That Held the DJIA Higher on Thursday at 24/7 Wall St.
01:04PM  MERCK & CO., INC. Financials
12:13PM  Merck & Co., Inc. (MRK), Monster Beverage Corp (MNST) Jump On Analyst Upgrades at Insider Monkey
11:54AM  Merck's stock surges on heels of analyst upgrade at MarketWatch
11:34AM  Gilead Sciences: Why Hepatitis-C Sales Could Fall Short at
10:26AM  Big Pharma firm, cancer hospital partnership to speed up drug development process at
10:02AM  Kim Kardashian, Dr. Oz And TV Drug Ads at Forbes
09:35AM  Theravance, Inc. Earnings Q2*, 2015
09:20AM  Immune Design's Q2 Loss Narrows Y/Y, Focus on Pipeline
08:51AM  Merck (MRK) Stock Upgraded at BMO Capital Markets at TheStreet
08:40AM  Top Analyst Upgrades and Downgrades: Alibaba, Baker Hughes, GoPro, Merck, Microsoft, Yahoo and Many More at 24/7 Wall St.
08:20AM  Analysts' Actions -- Capital One, Merck, Microsoft and More
08:12AM  Early movers: KSS, MRK, COTY, TSLA, MNST & more at CNBC
08:00AM  Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors Business Wire
Aug-12-15 05:03PM  Pfizer Stock Is Like An Extended Release Drug at Investopedia
12:59PM  Make Room for Exelixis in Your Portfolio at Investopedia
12:30PM  Checkmate Pharma is latest cancer drug firm focused on immune system (BBJ photo gallery) at
12:20PM  Sigma-Aldrich's Buyout by Merck KGaA Cleared in Brazil
10:19AM  5 Things Merck Wants You to Know at Motley Fool
09:45AM  Short Sellers Back Off Big Pharma at 24/7 Wall St.
Aug-11-15 02:55PM  Heres why Vertex fell short on its job-creation vows to the city at
09:55AM  Seattle's Immune Design teams up with Merck, stock soars at
Aug-10-15 02:45PM  Germantown synthetic biology company acquires firm specializing in insect control at
08:00AM  Immune Design and Merck to Collaborate on Combination Trials of Two Immune Design Immunotherapies With Merck's KEYTRUDA for Non-Hodgkin's Lymphoma and Melanoma GlobeNewswire
Aug-07-15 01:55PM  Merck KGaA's Net Income Up Y/Y, 2015 View Retained - Analyst Blog
08:07AM  Better Dividend Stock: Bristol-Myers Squibb or Merck? at Motley Fool
Aug-06-15 06:14PM  Vanguard Health Care Fund Buys 2 New Stakes in Second Quarter
04:38PM  MERCK & CO., INC. Files SEC form 10-Q, Quarterly Report
08:35AM  4 Large Cap Pharmaceutical Stocks to Buy on Strong Health Care Trends at 24/7 Wall St.
Aug-05-15 08:06AM  WeWork seeks new lease of life for the office model at Financial Times
Aug-04-15 02:51PM  Merck (MRK) Stock Price Target Increased at Leerink at TheStreet
01:27PM  Only two Ebola cases reported in past week, but risks remain - WHO
12:05PM  E.I. du Pont de Nemours & Co. Earnings Q2*, 2015
11:00AM  Big Pharma Tops Q1 Earnings & Revenue: ETFs in Focus - ETF News And Commentary
09:35AM  UBS Makes August Changes to Equity Focus List Portfolio at 24/7 Wall St.
07:56AM  Merck & Co., Inc. Earnings Analysis: By the Numbers Q2*, 2015
Aug-03-15 03:47PM  Madison Street Partners Reshuffles Its Portfolio and Bets on ETFs; See Its Top Stock Picks at Insider Monkey
11:05AM  Positive Developments Around Ebola at 24/7 Wall St.
Aug-01-15 02:24AM  Guinea Plans Ebola Inoculation Campaign
02:24AM  Guinea Plans Ebola Inoculation Campaign After Vaccine Success at Bloomberg
Jul-31-15 10:27PM  WHO Says Ebola Vaccine Effective in African Trial at The Wall Street Journal
06:57PM  WHO Says Ebola Vaccine Possibly Effective in Trial at The Wall Street Journal
04:24PM  Ebola game changer?
02:18PM  There's more to Merck's Ebola vaccine than money at CNBC
02:12PM  5 Key Points You May Have Missed in Merck's Q2 Report at Motley Fool
02:06PM  Experimental Ebola vaccine could stop virus in West Africa
01:48PM  Merck: Study shows potential Ebola vaccine has '100 percent efficacy' at
11:50AM  Merck should follow GSKs lead and commit to selling its potential Ebola vaccine at cost at
Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck & Co. Inc formerly operated as a subsidiary of Merck KGaA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Holston Michael JEVP, General CounselAug 01Option Exercise0.0022,584062,584Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Option Exercise39.8335,5421,415,54643,994Aug 04 02:41 PM
Golestani ClarkEVP & Chief Info OfficerJul 31Sale59.0931,8311,880,80512,163Aug 04 02:41 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 11Sale60.4410,634642,7680May 11 05:48 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Option Exercise35.2846,2081,630,39670,353May 11 01:33 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 08Sale60.9938,3682,339,94931,985May 11 01:33 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Option Exercise39.2956,0642,202,755206,496May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 04Sale60.2056,0643,374,795150,432May 05 04:46 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,818025,359May 05 04:46 PM
Golestani ClarkEVP & Chief Info OfficerMay 02Option Exercise0.002,291010,259May 05 04:46 PM
GRADDICK WEIR MIRIAN MExe V-P, HRMay 02Option Exercise0.008,6540116,334May 05 04:46 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 02Option Exercise0.004,709015,129May 05 04:46 PM
Rosenblatt MichaelExec V-P & Chief Med OfficerMay 02Option Exercise0.003,818034,534May 05 04:46 PM
Schechter Adam HEVP & Pres-Global Human HealthMay 02Option Exercise0.0019,343019,343May 05 04:46 PM
Kuhlik Bruce NExe V-P & Gen CounselMay 02Option Exercise0.0011,7080156,503May 05 04:46 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 02Option Exercise0.003,818020,794May 05 04:46 PM
Deese Willie AExe V-P & Pres. MMDMay 02Option Exercise0.007,6360122,631May 05 04:46 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthMay 02Option Exercise0.005,090014,564May 05 04:46 PM
Holston Michael JEVP, LegalApr 29Option Exercise44.39135,6246,020,460135,624Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Option Exercise38.51156,9026,042,441301,697Apr 29 06:01 PM
Holston Michael JEVP, LegalApr 29Sale59.8495,6245,722,54240,000Apr 29 06:01 PM
Kuhlik Bruce NExe V-P & Gen CounselApr 29Sale59.82156,9029,386,646144,795Apr 29 06:01 PM
HARRISON WILLIAM B JRDirectorApr 13Option Exercise33.835,000169,15011,400Apr 13 05:24 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Option Exercise31.847,082225,491358,564Feb 18 04:51 PM
FRAZIER KENNETH CChairman, President & CEOFeb 18Sale58.675,164302,959353,400Feb 18 04:51 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Option Exercise40.44135,8645,494,524242,094Feb 11 02:19 PM
Deese Willie AExe V-P & Pres. MMDFeb 11Sale58.56135,8647,956,372106,230Feb 11 02:19 PM
WENDELL PETER CDirectorFeb 09Option Exercise33.835,000169,1506,000Feb 09 03:24 PM
WENDELL PETER CDirectorFeb 09Sale58.765,000293,7971,000Feb 09 03:24 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Option Exercise41.1874,2003,055,57874,200Jan 15 03:55 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 15Sale62.4874,2004,636,2240Jan 15 03:55 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Option Exercise34.2012,874440,240360,322Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEOJan 09Sale62.478,840552,267351,482Jan 09 02:44 PM
FRAZIER KENNETH CChairman, President & CEODec 10Option Exercise34.2012,874440,240357,294Dec 10 05:59 PM
FRAZIER KENNETH CChairman, President & CEODec 10Sale60.009,846590,760347,448Dec 10 05:59 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Option Exercise51.0250,0002,551,000178,467Dec 08 06:55 PM
Kuhlik Bruce NExe V-P & Gen CounselDec 08Sale62.0050,0003,100,000128,467Dec 08 06:55 PM
LAZARUS ROCHELLE BDirectorNov 26Option Exercise34.1410,000341,35014,595Nov 26 12:40 PM
LAZARUS ROCHELLE BDirectorNov 26Sale59.6310,000596,3004,595Nov 26 12:40 PM
WEEKS WENDELL PDirectorNov 24Option Exercise33.835,000169,1505,100Nov 25 07:08 PM
WEEKS WENDELL PDirectorNov 24Sale59.135,000295,663100Nov 25 07:08 PM
FRAZIER KENNETH CChairman, President & CEONov 10Option Exercise34.2012,875440,272354,420Nov 10 04:36 PM
FRAZIER KENNETH CChairman, President & CEONov 10Sale57.9810,000579,784344,420Nov 10 04:36 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthNov 02Option Exercise0.004,38704,387Nov 03 04:46 PM
FRAZIER KENNETH CChairman, President & CEOOct 10Option Exercise34.2012,875440,272351,440Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOOct 10Sale59.739,895591,033341,545Oct 14 09:05 AM
FRAZIER KENNETH CChairman, President & CEOSep 10Option Exercise34.2012,875440,272348,379Sep 10 01:53 PM
FRAZIER KENNETH CChairman, President & CEOSep 10Sale60.489,814593,592338,565Sep 10 01:53 PM